Nuvectis Pharma logo

Nuvectis PharmaNASDAQ: NVCT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 February 2022

Next earnings report:

07 May 2025

Last dividends:

N/A

Next dividends:

N/A
$100.08 M
-66%vs. 3y high
45%vs. sector
-vs. 3y high
-vs. sector
-60%vs. 3y high
91%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 115 min ago
$5.18-$0.21(-3.90%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

NVCT Latest News

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
benzinga.com14 November 2024 Sentiment: NEGATIVE

Nuvectis Pharma, Inc. NVCT stock is trading lower after the company reported data from the Phase 1b study evaluating NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer.

Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why
zacks.com13 November 2024 Sentiment: POSITIVE

Nuvectis Pharma (NVCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
zacks.com07 November 2024 Sentiment: POSITIVE

The consensus price target hints at a 169.9% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
globenewswire.com05 November 2024 Sentiment: POSITIVE

FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter of 2024 and provided an update on recent business progress.

Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
zacks.com24 May 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 229.3% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
GlobeNewsWire09 February 2024 Sentiment: POSITIVE

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:

Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)
Zacks Investment Research16 October 2023 Sentiment: POSITIVE

The heavy selling pressure might have exhausted for Nuvectis Pharma, Inc. (NVCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
GlobeNewsWire25 September 2023 Sentiment: POSITIVE

Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 2023 Cantor Global Healthcare Conference Corporate Presentation, as follows:

Nuvectis: Early Stage Company That's Low On Cash
Seeking Alpha06 September 2023 Sentiment: NEGATIVE

Nuvectis is developing precision medicines for cancer patients, with lead asset NXP800 targeting ARID1a-mutated ovarian cancer. Preclinical trials have shown strong antitumor activity of NXP800, including in cisplatin resistant patients. NVCT also has a second asset, NXP900, which has shown significant single-agent activity in squamous cell cancer models.

Here's Why Momentum in Nuvectis Pharma, Inc. (NVCT) Should Keep going
Zacks Investment Research05 June 2023 Sentiment: POSITIVE

Nuvectis Pharma, Inc. (NVCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

What type of business is Nuvectis Pharma?

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

What sector is Nuvectis Pharma in?

Nuvectis Pharma is in the Healthcare sector

What industry is Nuvectis Pharma in?

Nuvectis Pharma is in the Biotechnology industry

What country is Nuvectis Pharma from?

Nuvectis Pharma is headquartered in United States

When did Nuvectis Pharma go public?

Nuvectis Pharma initial public offering (IPO) was on 04 February 2022

What is Nuvectis Pharma website?

https://www.nuvectis.com

Is Nuvectis Pharma in the S&P 500?

No, Nuvectis Pharma is not included in the S&P 500 index

Is Nuvectis Pharma in the NASDAQ 100?

No, Nuvectis Pharma is not included in the NASDAQ 100 index

Is Nuvectis Pharma in the Dow Jones?

No, Nuvectis Pharma is not included in the Dow Jones index

When was Nuvectis Pharma the previous earnings report?

No data

When does Nuvectis Pharma earnings report?

The next expected earnings date for Nuvectis Pharma is 07 May 2025